RNA Interference Drug Excels in Clinical Trials to Treat Rare Disorder
Alnylam Pharmaceuticals is reporting positive results from a clinical trial using patisiran—an RNA interference (RNAi) drug—to treat patients suffering from hereditary amyloidosis with polyneuropathy, a